Roth Capital Has Pessimistic View of InfuSystem Q4 Earnings

InfuSystem Holdings, Inc. (NYSE:INFU) – Equities researchers at Roth Capital dropped their Q4 2025 earnings per share (EPS) estimates for InfuSystem in a research report issued to clients and investors on Tuesday, August 5th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings of $0.05 per share for the quarter, down from their prior forecast of $0.06. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. Roth Capital also issued estimates for InfuSystem’s Q2 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.34 EPS and FY2027 earnings at $0.50 EPS.

Several other equities research analysts also recently commented on INFU. B. Riley upgraded InfuSystem to a “strong-buy” rating in a report on Thursday, May 8th. Wall Street Zen cut shares of InfuSystem from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 14th.

InfuSystem Stock Up 4.9%

Shares of NYSE:INFU opened at $7.52 on Thursday. The stock has a 50-day simple moving average of $6.04 and a 200-day simple moving average of $6.17. The stock has a market capitalization of $158.04 million, a P/E ratio of 125.35 and a beta of 1.81. InfuSystem has a 1 year low of $4.61 and a 1 year high of $9.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INFU. Minerva Advisors LLC increased its holdings in shares of InfuSystem by 7.5% in the first quarter. Minerva Advisors LLC now owns 910,677 shares of the company’s stock valued at $4,899,000 after buying an additional 63,826 shares in the last quarter. Meros Investment Management LP grew its holdings in shares of InfuSystem by 2.6% in the 4th quarter. Meros Investment Management LP now owns 631,105 shares of the company’s stock worth $5,333,000 after acquiring an additional 16,178 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of InfuSystem by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 456,043 shares of the company’s stock worth $3,853,000 after purchasing an additional 21,697 shares during the period. Geode Capital Management LLC raised its position in shares of InfuSystem by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 444,476 shares of the company’s stock worth $3,756,000 after purchasing an additional 7,968 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of InfuSystem by 13.1% during the first quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company’s stock valued at $2,356,000 after purchasing an additional 50,877 shares during the last quarter. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.